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Abstract:  This paper presents a generally applicable approach for the 
highly specific detection of blood proteins. Thrombin and thrombin-binding 
aptamers are chosen for demonstration purposes. The sensor was prepared 
by immobilizing amine-terminated aptamers onto a gold modified surface 
using a two-step self-assembled monolayer (SAM) immobilization 
technique and the physical detection is performed using Surface Plasmon 
Resonance (SPR). The developed sensor has an optimal detectable range of 
5–1000 nM and the results show the sensor has good reversibility, 
sensitivity and selectivity. Furthermore, the sensor shows the potential of 
being improved and standardized for direct detection of other blood proteins 
for clinical applications. 
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1. Introduction 
The direct detection of blood proteins can benefit a number of scientific and clinical 
applications, such as in monitoring the ratio of specific protein glycation in diabetes [1], 
biomarkers for drug research and environmental monitoring [2], cancer diagnostics and 
treatment [3], etc. The current clinical and laboratory measurement techniques for blood 
proteins are boronate affinity immunoassay, high-performance liquid chromatography 
(HPLC) and capillary based systems [4–6], which are time consuming and costly. More 
efficient and fast response measurement methods could greatly benefit and enhance related 
application areas, especially for developing the next generation of portable handheld 
diagnostic devices capable of real-time analysis. Several optics-based diagnostic techniques, 
such as near-infrared spectroscopy [7,8], polarimetry [9], optical coherence tomography [10], 
Surface Plasmon Resonance (SPR) [11], Raman [12] and fluorescence spectroscopy [13] have 
recently been investigated for monitoring blood components. Changes in optical properties 
resulting from variations in blood components/chemistry provide a convenient method for the 
use of optical diagnostic techniques to provide for fast and in vivo measurements. In this 
paper, an approach is presented for the detection of specific blood proteins based on custom 
SPR aptamer modified sensors that can have broad applications. 
Aptamers are artificial oligonucleotides which can serve as antibody mimics because of 
their high affinity and selectivity for various target compounds ranging from small molecules, 
such as drugs and dyes, to complex biological molecules such as enzymes, peptides, and 
proteins. Custom aptamers can be identified from random oligonucleotide libraries for 
specific target compounds by an in vitro  iterative process called Systematic Evolution of 
Ligands by Exponential Amplification (SELEX) [14,15]. Aptamers can form a 3D structure 
serving as receptors specific to their target molecules similar to antibodies. Aptamers also 
have a number of advantages over antibodies such as a tolerance to wide ranges of pH and salt 
concentrations, heat stability, ease of synthesis, and cost efficiency. The specificity and 
affinity of aptamers are comparable, if not higher, to antibodies. Aptamers are also capable of 
being reversibly denatured for the release of target molecules, which makes them perfect 
receptors for biosensing applications. 
SPR is a member of a family of spectroscopic techniques based on evanescent wave 
optics. It is commonly used for determination of refractive index, dielectric constant, and 
layer thickness with high sensitivity. By itself, however, SPR is not a selective sensing 
technique and requires adaptation for specific target identification and quantification. 
Therefore, a number of SPR-based biosensors have been recently reported on for a variety of 
environmental and biological applications [16]. 
Some groups have successfully developed aptamer-based biosensors for the detection of 
proteins [17–24] and related SPR based sensors have also been reported [25,26]. Use of a self-
assembled monolayer (SAM) as a linker and coadsorbent thiol-modified aptamers together to 
form a aptamer-SAM matrix on a gold surface has demonstrated its potential as a reliable and 
easy approach [27]. However, the cost of the thiol-modified aptamers is much higher than the 
non-modified or amine-modified aptamers. The uniformity and density of the SAM are also 
not guaranteed from sample to sample. We report on a 3-mercaptopropionic acid (MPA) SAM 
based coupling approach for a more stable and repeatable modification of the sensor surface. 
Electrochemical Impedance Spectroscopy (EIS) was utilized to monitor the formation of the 
SAMs on the gold surfaces. Aptamer binding capacity was then determined by a magnetic 
beads (MBs) coupling method. The developed sensor has an optimal detectable range of 5-
1000 nM with good reversibility, sensitivity and selectivity. Furthermore, the sensor shows 
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proteins for clinical applications. 
2. Materials and Experimental 
2.1. Materials 
The identified aptamers were synthesized by Integrated DNA Technologies (Coralville, IA), 
including a 15bp aptamer (APT1): 5′-NH2-(CH2)6-GGTTGGTGTGGTTGG-3′, and a 34bp 
aptamer (APT2): 5′-NH2-(CH2)6-CTATCAGTCCGTGGTAGGGCAGGTTGGGGTGACT-3′. 
Tosylactivated MBs were purchased from Invitrogen (Carlsbad, CA). All other chemicals 
were purchased from Sigma Aldrich (Carlsbad, CA) at the highest purity available. Aptamer 
solutions were prepared with 1M pH 8 phosphate buffer and 3-mercaptopropionic acid (MPA) 
solution was prepared in ethanol. Protein sample solutions were prepared using a 0.1M pH 7.2 
PBS buffer solution with 5 mM KCl and 1 mM MgCl2. The phosphoric acid (PPA) used in 
this study was 100 mM. All other solutions were prepared in deionized (DI) water. 
2.2. Instrumentation 
SPR measurements were performed using a commercial grade SensiQ Discovery system (ICx 
Technologies, Arlington, VA) at 25°C. This sensor is based on a Kretschmann configuration, 
in which the light from a light-emitting diode (LED) integrated with a prism is firstly p-
polarized and then internally reflected from a gold surface. The angle of light reflection and 
the relative intensity was measured with a photodiode array. When the sample solution is 
applied to the sensing surface, the SPR profile minimum (also known as the SPR angle) will 
shift as a function of the refractive index of the loaded sample, giving a real time refractive 
index reading (although, by itself the sensor is not specific/selective for any given target). In 
this study, the SPR response profile was recorded by the SensiQ software and then processed 
within MATLAB
®. 
2.3. Experimental 
Electrochemical impedance spectroscopy (EIS) measurements were carried out using a Gamry 
Reference 600 potentiostat (Warminster, PA) in 5 mM Fe(CN)6
3-/Fe(CN)6
4- solution with KCl 
as a supporting electrolyte. All the experiments were carried out at room temperature with the 
solutions purged with nitrogen gas for 15 minutes and the nitrogen blanket was maintained 
during the experiments. The experiments were performed at 25°C. Impedance spectra were 
collected in the frequency range from 0.1 Hz to 100 kHz with a potential amplitude of 5 
mVrms  at 10 points per decade. EIS results were analyzed by fitting the experimental 
impedance data to electrical equivalent circuit models. Parameters of the electrical-equivalent 
circuits were obtained by fitting the impedance function to the measured Bode and Nyquist 
plots with a complex nonlinear least square (CNLS) program built into the Gamry EIS 300 
electrochemical impedance spectroscope. 
Aptamer coupling to the MBs was performed as followed: 10 nmol of amine modified 
aptamer was coupled to 10 mg washed MBs in a shaker incubator at 37°C for 18 hours. The 
unoccupied binding sites were blocked by Bovine Serum Albumin (BSA). The MBs were 
washed thoroughly and then 10 nmol of thrombin was mixed with the aptamer-coupled MBs 
for 2 hours in a shaker at room temperature. The control group was prepared by exactly the 
same method except for the absence of aptamers. The total and unbounded proteins were 
measured with a carboxyl functionalized SPR sensor provided by SensiQ. 
To use an aptamer-based SPR sensor for detecting blood proteins, thrombin and anti-
thrombin aptamer were chosen for demonstration purposes. Gold slides were prepared by 
physical vapor deposition (PVD) forming a 1 nm layer of titanium and a 50 nm layer of gold 
onto pre-cleaned microscope cover slides. These were then washed by copious amounts of DI 
water and ethanol. They were dried in nitrogen gas before usage. To functionalize the gold 
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ethanol and DI water. After the slides were dried, then they were immersed in a solution of  
N-hydroxysuccinimide (NHS) and N-(3-dimethylamnopropyl)-N-ethylcarbodiimide 
hydrochloride (EDC) (NHS 0.2M, EDC 0.05M) for 30 min. The slides were then washed with 
DI water and then immersed in the 5 μM aptamer solution. Finally, the slides were rinsed with 
the PBS buffer to flush off non-specifically adsorbed proteins. Then the slides were ready for 
measurement. This two-step surface functionalization procedure is illustrated in Fig. 1. 
Non-coated (i.e. no gold) SensiQ base sensors were custom modified with the developed 
gold based SPR sensing surfaces. Specifically, freshly prepared aptamer- immobilized gold 
substrates were coupled to the stripped sensors with index matching optical oil. This was 
followed by then loading of 100μL 1 M ethanolamine (EA) at a flow rate of 20 μL/min to 
block the non-occupied MPA sites activated by the EDC/NHS, followed by an injection of 
100 μL of 100 mM phosphoric acid (PPA) at 50 μL/min to remove the non-specific binding. 
The running buffer was 0.1 M pH 7.2 PBS. The sensor was first normalized with the buffer 
for 10 min, then the thrombin sample (25 μL) at concentrations of 5 nM, 25 nM, 50 nM, 250 
nM  500  nM,  1000  nM,  2000  nM  were  loaded  at  5  μL/min.  Samples  with  BSA  were  all 
prepared with 400 nM BSA. All data was recorded at 290s, 300s, and 310s after the sample 
injection and averaged. Sensor regeneration was performed by the injection of 100 μL PPA at 
50 μL/min followed by washing with the running buffer. 
 
Fig. 1. Schematic diagram of the sensing surface functionalization procedure. 
3. Results and Discussion 
3.1. EIS measurement 
Electrochemical impedance spectroscopy (EIS) has been proven as a powerful tool for surface 
characterization. The successful immobilization of each functionalized layer was confirmed 
through EIS measurements. Figure 2  shows the Nyquist plots of impedance spectra at 
different electrodes. The bare gold electrode represented a very small circle at high 
frequencies, suggesting a very low electron transfer resistance to the redox probe dissolved in 
the electrolyte solution (curve A). When the MPA was immobilized on the electrode and 
treated with EA and PPA, the electron transfer resistance (Ret) increased to 125 Ω, (curve B). 
Then, when 5 μM of the APT1 aptamer was added and bound with the SAM, Ret increased to 
600 Ω (curve C). Note that the reactive  sites on the  gold electrode were blocked by EA 
(ethanolamine) to prevent non-specific adsorption of aptamers onto the gold surface, thus 
making sure that the aptamers were attached only to the SAM. The Ret increase is attributed to 
the electrostatic repulsion between the immobilized aptamer and the redox probe, causing a 
barrier for the interfacial electron transfer. These results indicate successful immobilization of 
the SAM layer onto the gold surface and stable bonding of the aptamer to the SAM. 
3.2. MB based maximum binding capacity study 
It is assumed that all aptamers were coupled to the MBs completely since twice the amount of 
the MBs, as instructed by the MB manufacturer’s protocol sheet, were used along with the  
 
#151418 - $15.00 USD Received 20 Jul 2011; revised 10 Aug 2011; accepted 12 Aug 2011; published 31 Aug 2011
(C) 2011 OSA 1 September 2011 / Vol. 2,  No. 9 / BIOMEDICAL OPTICS EXPRESS  2735 
Fig. 2. Nyquist plots of impedance spectra obtained in 100 mM PB solution (pH 7.2) 
containing 5 mM Fe(CN)6
3-/Fe(CN)6
4-: (A) Bare Au; (B) Au/MPA/EDC-NHS/EA/PPA; (C) 
Au/MPA/EDC-NHS/EA/PPA/APT1. The right plot shows the (Ret) of each layers. Impedance 
spectra were collected in the frequency range from 0.1 Hz to 100 kHz with a potential 
amplitude of 5 mV rms at 10 points per decade. 
longest allowed reaction time. After the modified MBs were thoroughly washed, thrombin 
was added and the concentration change was measured using a carboxyl modified SPR sensor. 
It is also assumed that the refractive index is controlled only by the concentration change of 
the added thrombin. 
Other experimental variables such as protein degeneration and temperature had minor 
influences on SPR results and thus were not considered. As shown in Fig. 3, the concentration 
change of thrombin was insignificant for the control group (less than 3%) which was not 
functionalized by the aptamer. This indicates  that the concentration change in the two 
experimental groups was mainly due to the binding between the aptamer and thrombin. For 
the APT1 and APT2 groups, the mixture of aptamer functionalized MBs and thrombin 
solution was allowed to react for 18 hours and the reaction was considered to be completed 
based on the MB manufacturer’s specifications (see section 2.3 for the experimental details). 
Thus, the final concentration reflected the maximum mol/mol binding capacity of aptamer to 
thrombin. The results showed the binding ratio of APT1 (57.1%) has a slightly better capacity 
than APT2 (55.2%). Both aptamers had more than 50% mol/mol binding ratio to thrombin,  
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Fig. 3. Aptamer/thrombin binding ratio in mol by the MBs coupling method. 
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practice, not all the aptamers may bind to the MBs and therefore the actual binding capacity of 
two thrombin binding aptamers toward thrombin may be slightly  greater. It should be 
mentioned that MBs binding to aptamers could form a MB-based biosensor by involving 
fluorescence labeling [28], however, the sample preparation procedure of this method is 
complicated. Here we only utilized the MBs to determine the maximum binding capacity of 
the aptamers used in this study. This could facilitate choosing the best aptamer from multiple 
candidates in future optimization studies. 
The Control group consists of MBs without aptamer functionalization and all binding sites 
blocked by BSA. The APT1 and APT2 groups consist of MBs functionalized by the 
respective aptamers with the unoccupied binding sites blocked by BSA. The error bars 
represent the standard deviation of the values determined from three samples. 
3.3. SPR results 
Two different aptamers were immobilized on gold surfaces and the binding performance of 
each one was compared. For reference, samples of different thrombin concentrations (5 nM, 
25 nM, 50 nM, 250 nM, 1000 nM, 2000 nM) were individually loaded onto a bare Au, an 
APT1, and APT2 sensor, respectively. A secondary experiment was then performed using the 
same thrombin concentrations, however, with a 400nM BSA confounding component added 
to each thrombin sample for comparison. As shown for the “Thrombin only” experiment in 
Fig. 4, the SPR shifts were very low for the bare Au sensor surface even for the relatively high 
thrombin concentrations; which was expected. In contrast, for the aptamer modified sensors 
the SPR shifts were significantly enhanced and the optimal detection range was 5 nM to 1000 
nM (linear range). As shown in the “Thrombin + 400 nM BSA” experiment in Fig. 4., the 
prior experiment was replicated, however, with a large 400nM BSA confounding 
concentration component added to each thrombin sample concentration. As compared to the 
thrombin only group, the responses are nearly identical indicating the developed APT1 and 
APT2 sensors are highly specific to only thrombin; which was expected. This is further 
illustrated in Fig. 5, which shows the SPR shift for the 500 nM thrombin concentration with 
and without 400 nM of BSA. Adding BSA to the sample had minimal effect on the SPR 
response for the aptamer modified sensors, indicating a good selectivity of the sensor toward 
thrombin. This is in contrast to the bare Au sensor, which experienced a significant change 
between the thrombin samples with and without BSA. The APT1 modified sensor did have a 
slightly higher shift than the APT2 sensor for all the thrombin concentrations. The slope of the 
fitting line for APT1 is also slightly larger than APT2 in the linear response range (Fig. 6), 
again demonstrating a slightly better sensitivity. These two aptamers bind to different sites of 
thrombin, thus the affinity to the target should be different in both the interfacial binding 
environment and in solution [29]. In the MBs binding tests, we demonstrated that APT1 had a 
slightly higher binding capacity than APT2, which corresponds to the SPR results in terms of 
sensitivity of the functionalized sensor. A potential cause of this could be due to the smaller 
aptamer having a greater probability to access the binding sites of the target protein. Another 
possibility is that larger aptamers are thought to have more complicated secondary structures 
that require an extra spatial flexibility to form bonding with target molecules [30]. 
The MPA layer is known to have excellent coverage rate on gold and is widely used for 
antibody immunization for biosensing purposes [29]. MPA is cost effective and the related 
SAMs are easy to prepare. Our results show that the amine-modified aptamer can be easily 
immobilized onto the MPA layer and the sensor performance was comparable to antibody-
based sensors. Imprecision guidelines for blood proteins quantification has been proposed by 
several reports and the common finding is that an imprecision of 3% for quantification 
methods is adequate for clinical purposes [28,31,32]. In our tests, three sensing slides were 
prepared for each aptamer and also the control group. The sensor to sensor performance was  
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Fig. 4. SPR response of bare Au and aptamer-modified sensors. All data points were averaged 
from 3 experimental data readings. Samples were thrombin only (top plot) and thrombin with 
400 nM BSA (bottom plot). The inlay plots are same data plotted on logarithmic scale to allow 
for better visualization at lower concentrations. 
 
Fig. 5. SPR responses of different sensing surfaces for 400 nM BSA (BSA group), 500 nM 
thrombin (Thrombin group), and 500 nM thrombin with 400 nM BSA (Thrombin + BSA 
group). The error bars represent the standard deviation of the values determined from three 
freshly prepared samples. 
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measurement and averaging less than 2% standard deviation of the total signal (error bar 
showed in Fig. 5). Adding BSA did introduce a slightly larger error and by lowering the flow 
rate and increasing the sample loading time, the error can be reduced although deemed not 
significant enough to be considered. The majority of the error is thought to be caused by 
temperature variance; thereby placing the sensor in a temperature controlled environment 
should help increase the accuracy. Recently, aptamer immobilization has been done on a 
variety of surfaces for sensing purposes such as magnetic nanoparticles [33], gold 
nanoparticles [34], and carbon nanotubes [35]. Our sensing surface in this study had an 
optimal dynamic range from 5 nM to 1000 nM, which is comparable to or greater than the 
largest reported dynamic  ranges for thrombin aptamer-based sensing techniques. The 
thrombin concentration range in the human blood is reported to be within the low nanomolar 
to low micromolar range [36], suggesting that the reported method could be well suited for 
potential in vivo thrombin quantitative detection. 
 
Fig. 6. SPR responses of different sensing surfaces for 50 nM, 250 nM, 500 nM thrombin with 
and without 400 nM BSA, upper axis (APT1), lower axis (APT2); The zero position of lower 
axis has been shifted intentionally to better distinguish between data points that would be 
overlapping. 
To test the reversibility of the sensor, fixed sample concentrations were repeatedly loaded 
to the sensor 10 times. The sensor regeneration was done by PPA, as previously described. 
The average SPR response with error bars for standard deviation using thrombin 
concentrations of 50 nM, 250 nM and 500 nM are shown in Fig. 6. All data were obtained 
from freshly prepared sensing slides. According to our experience, the SPR response would 
decrease about 0.5% for each loading for a same sample concentration. All the sensing slides 
maintained more than 95% of the original SPR shift response after the 10th loading. It was 
also noticed that the second sample loading usually had the greatest response change as 
compared to the following loadings. We expect that with a longer PPA injection time, the 
sensor recovery rate can be increased, depending on the experimental requirements. The 
appearance of BSA did lower the sensitivity of the sensor (e.g. in Fig. 6, the appearance of 
BSA did reduce the slope slightly in the response curve), although it did not affect the 
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and without the appearance of BSA in the 50 nM to 500 nM sample range. 
3.4. Further optimization and development of the sensor 
Better performance of the sensor may be possibly achieved by using a mixed length spacer 
layer [37], such as 11-mercaptoundecanoic acid (MUA) combined with MPA to increase the 
sensitivity and specificity [38]. Such a configuration could potentially help form and maintain 
the specific shape of the immobilized aptamers. Furthermore, inserting a hydrophilic group 
such as ethylene oxide onto the 5′-end of the aptamer may reduce nonspecific protein binding 
[27]. However, using our two-step immobilization method, in which a SAM was first 
immobilized followed by the aptamers, this should be a more cost effective and controllable 
method compared to adding all of the modifications to the aptamer monomer at once. 
Consequently, by specifically designing the SAM, e.g. optimizing the hydrocarbon length and 
introducing co-adsorbents [39], we can still use the simple amine-modified aptamer as the 
receptor to improve the sensitivity and selectivity. 
Since the surface density of immobilized aptamer affects the efficiency of target capture, 
and the surface coverage was mainly determined by the aptamer immobilization 
concentrations [29],  here  we  used  relatively  high  aptamer  concentrations  (i.e.  5  μM)  to 
guarantee the density and the uniformity of the surface. However, closely packed aptamers 
might prevent the target molecules from approaching their respective binding sites efficiently, 
and at meantime, they may inhibit themselves from folding into secondary structures. 
Therefore, by optimizing the aptamer immobilization concentrations, the performance of the 
sensor may be improved. For the two step immobilization method, spacing the aptamers could 
be also done by adjusting the MPA SAM density, or by co-incubating ethanolamine and the 
aptamer at various molar ratios. 
For the detection of different blood proteins, the key factor is to find the aptamer that 
specifically and directly binds to the target protein of interest [40], which can be achieved 
using a SELEX procedure. Then, the developed aptamer can then be amine-terminated and 
immobilized onto the gold surface based on the same methods described in this paper to form 
a target specific sensor for almost any protein. 
4. Conclusions 
Aptamers can be generated through SELEX to target specific molecules with advantages over 
antibodies. We have demonstrated a two-step procedure for the immobilization of a SAM and 
amine-terminated aptamer onto a gold SPR sensing surface. The advantages of the SPR 
sensor, such as low sample consumption, the lack of labeling requirement, high sensitivity, 
and fast response have been demonstrated. Also, the advantages of the two-step 
immobilization method has demonstrable cost efficiency, good reversibility uniform density, 
and shows promise for the eventual development of a robust and specific blood protein 
detection platform. 
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